Pomdoctor shares surge 14.23% premarket after announcing pharma partnerships to expand internet hospital business.

POMDOCTOR surged 14.23% in premarket trading following the announcement of strategic collaborations with leading pharmaceutical companies to accelerate growth in its internet hospital business. The company highlighted partnerships with firms like Jiangsu Haosoh and Xiamen Amoytop, enabling the introduction of innovative pharmaceutical products on its platforms while securing favorable purchase discounts and sales incentives. These collaborations aim to enhance profitability, expand market presence, and streamline the pharmaceutical supply chain, aligning with China’s rapidly growing online drug sales market, which reached RMB 71.8 billion in 2024. The CEO emphasized the model’s potential to reshape traditional distribution by reducing intermediaries and improving efficiency, transparency, and accessibility. The move underscores Pomdoctor’s focus on leveraging market dynamics in China’s aging population and healthcare reforms to drive long-term value.